Company / Net Income
RAPT Therapeutics, Inc. Net Income History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$129.9M
FY2024
5-year range
-$129.9M / -$52.9M
FY2020-FY2024
Trend
-11.2%
vs FY2023
Sector context
#125 of 215
Health Care
What the data says
At -$130M, RAPT Therapeutics, Inc.'s net income ranks #125 of 215 in the Health Care sector. Net Income has declined for 6 consecutive years, from -$36M in FY2018 to -$130M in FY2024.
Based on SEC 10-K filings.
-$130M in FY2024.
Declined from -$84M to -$130M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#125 of 215 in Health CareTop 58% of 215This company -$129.9M Sector average $431.3M
▼
-130.1% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s net income has declined for 6 consecutive years.
- In FY2024, net income decreased 11.2% year-over-year.
- Ranks #125 out of 215 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$129.9M | -11.2% |
| FY2023 | -$116.8M | -39.3% |
| FY2022 | -$83.8M | -21.1% |
| FY2021 | -$69.2M | -30.8% |
| FY2020 | -$52.9M | -23.0% |
| FY2019 | -$43.0M | -19.0% |
| FY2018 | -$36.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026